[en] FKBP51 (gene FKBP5) is an immunophilin capable of immunosuppression expressed in melanoma and lymphocytes. We found increased levels of a spliced FKBP5 variant in the PBMCs of 124 patients with melanoma. This variant encodes for an unknown isoform (FKBP51s). We hypothesized that FKBP51s resulted from tumour interaction with immune cells, through PDL-1/PD-1. To address this issue, we performed melanoma/PBMC cocultures. Furthermore, the immunohistochemistry of 76 melanoma specimens served to investigate whether FKBP51s stained tumour infiltrating lymphocytes. Our results showed that PBMCs expressed FKBP51s when cocultured with melanoma. Tumour PDL-1 knockdown or anti-PD-1 reduced FKBP51s expression in cocultured PBMCs. IHC showed a strong FKBP51s signal in tumour infiltrating lymphocytes, and lymphocytes of the invasion front of the tumour, along with melanoma PDL-1 expression. When overexpressed in melanoma, FKBP51s facilitated PDL-1 expression on the cell surface. In conclusion, our study shows that FKBP51s marks the PBMCs of patients with melanoma and is exploited by the tumour to immunomodulate through PDL-1.
Disciplines :
Immunology & infectious disease Oncology
Author, co-author :
Romano, Simona
D'Angelillo, Anna
Staibano, Stefania
Simeone, Ester
D'arrigo, Paolo ; Université de Liège - ULiège > I3-Virology and Immunology
Ascierto, Paolo Antonio
Scalvenzi, Massimiliano
Mascolo, Massimo
Ilardi, Gennaro
Merolla, Francesco
Jovarauskaite, Egle
Romano, Maria Fiammetta
Language :
English
Title :
Immunomodulatory pathways regulate expression of a spliced FKBP51 isoform in lymphocytes of melanoma patients.
Ascierto, P.A., Grimaldi, A.M., Acquavella, N. et al. (2013). Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012". J. Transl. Med. 11, 137.
Baughman, G., Wiederrecht, G.J., Campbell, N.F., Martin, M.M., and Bourgeois, S. (1995). FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol. Cell. Biol. 15, 4395-4402.
Blank, C., Brown, I., Amy, C., Peterson, A.C., Spiotto, M., Iwai, Y., Honjo, T., and Gajewski, T.F. (2004). PD-L1/B7H-1 Inhibits the effector phase of tumor rejection by T-cell receptor (TCR) transgenic CD8 + T Cells. Cancer Res. 64, 1140-1145.
Brahmer, J.R., Drake, C.G., Wollner, I. et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol. 28, 3167-3175.
Cheng, X., Veverka, V., Radhakrishnan, A. et al. (2013). Structure and interactions of the human programmed cell death 1 receptor. J. Biol. Chem. 288, 11771-11785.
Dornan, J., Taylor, P., and Walkinshaw, M.D. (2003). Structures of immunophilins and their ligand complexes. Curr. Top. Med. Chem. 3, 1392-1409, Review.
Greenwald, R.J., Freeman, G.J., and Sharpe, A.H. (2005). The B7 family revisited. Annu. Rev. Immunol. 23, 515-548. Review.
Ibbotson, T., McGavin, J.K., and Goa, K.L. (2003). Abciximab: an updated review of its therapeutic use in patients with ischaemic heart disease undergoing percutaneous coronary revascularisation. Drugs 63, 1121-1163.
Kern, G., Kern, D., Schmid, F.X., and Fischer, G. (1994). Reassessment of the putative chaperone function of prolyl-cis/trans-isomerases. FEBS Lett. 348, 145-148.
Labarrière, N., Gervois, N., Bonnin, A., Bouquié, R., Jotereau, F., and Lang, F. (2008). PBMC are as good a source of tumor-reactive T lymphocytes as TIL after selection by Melan-A/A2 multimer immunomagnetic sorting. Cancer Immunol. Immunother. 57, 185-195.
Liu, X.J., Zhang, J.F., Sun, B., Peng, H.S., Kong, Q.F., Bai, S.S., Liu, Y.M., Wang, G.Y., Wang, J.H., and Li, H.L. (2009). Reciprocal effect of mesenchymal stem cell on experimental autoimmune encephalomyelitis is mediated by transforming growth factor-beta and interleukin-6. Clin. Exp. Immunol. 158, 37-44.
Page, D.B., Postow, M.A., Callahan, M.K., Allison, J.P., and Wolchok, J.D. (2014). Immune modulation in cancer with antibodies. Annu. Rev. Med. 65, 185-202. Review.
Romano, M.F., Avellino, R., Petrella, A., Bisogni, R., Romano, S., and Venuta, S. (2004). Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur. J. Cancer 40, 2829-2836.
Romano, S., D'Angelillo, A., Pacelli, R. et al. (2010). Role of FK506-binding protein 51 in the control of apoptosis of irradiated melanoma cells. Cell Death Differ. 17, 145-157.
Romano, M.F., D'Angelillo, A., Romano, S., Ascierto, P.A., Simeone, E., Staibano, S., D'Arrigo, P., Scalvenzi, M., Ilardi, G., and Bisogni, R. (2014). The isoform 2 of FKBP51 is induced by PDL-1/PD1 interaction and marks peripheral blood mononuclear cells of melanoma patients. AACR - San Diego. Abstract n 2912, Personal Communication.
Romano, S., Staibano, S., Greco, A. et al. (2013). FK506 binding protein 51 positively regulates melanoma stemness and metastatic potential. Cell Death Dis. 4, e578.
Rudolph, B.M., Loquai, C., Gerwe, A., Bacher, N., Steinbrink, K., Grabbe, S., and Tuettenberg, A. (2014). Increased frequencies of CD11b(+) CD33(+) CD14(+) HLA-DR(low) myeloid-derived suppressor cells are an early event in melanoma patients. Exp. Dermatol. 23, 202-204.
Somarelli, J.A., Lee, S.Y., Skolnick, J., and Herrera, R.J. (2008). Structure-based classification of 45 FK506-binding proteins. Proteins 72, 197-208.
Somasundaram, R., Zaloudik, J., Jacob, L., Benden, A., Sperlagh, M., Hart, E., Marks, G., Kane, M., Mastrangelo, M., and Herlyn, D. (1995). Induction of antigen-specific T and B cell immunity in colon carcinoma patients by anti-idiotypic antibody. J. Immunol. 155, 3253-3261.
Topalian, S.L., Hodi, F.S., Brahmer, J.R., Gettinger, S.N., Smith, D.C., and McDermott, D.F. (2012). Safety, activity, and immune correlates of anti-PD1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454.
Yao, S., Zhu, Y., and Chen, L. (2013). Advances in targeting cell surface signalling molecules for immune modulation. Nat. Rev. Drug Discov. 12, 130-146.
